News

In March, the companies forged a collaboration to co-develop and supply potential mRNA-based coronavirus vaccines that include BNT162. The early-stage trial for the Covid-19 vaccine candidate is part of

In response to the COVID-19 pandemic, CIRM recently approved emergency funding and the allocation of $5 million for peer-reviewed regenerative medicine and stem cell research that could quickly

Based in South San Francisco of California, Portola is engaged in the discovery, development and commercialisation of novel therapeutics for thrombosis and other haematologic conditions. The company’s commercialised

“Receiving PRIME designation for sotatercept from the EMA mere weeks after the FDA granted it Breakthrough Therapy designation further strengthens our belief that sotatercept could eventually alter the

VIR-2703 is a result of the recently announced expansion of the firms’ multi-target existing collaboration for the development and commercialisation of RNAi therapeutics for infectious diseases. The partnership

LUNAR-COV19 utilizes Arcturus’ self-transcribing and replicating mRNA (STARR™) technology and the Company’s LUNAR® lipid-mediated delivery to produce an extraordinarily low dose, potential single shot COVID-19 vaccine. The manufacture

Junshi Biosciences, a Chinese biopharmaceutical company, is working to discover therapies to combat Covid-19 from the starting of the outbreak. The company has designed multiple neutralising antibodies and

Novartis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Enerzair® Breezhaler® (QVM149;

CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with AML, who achieved complete remission (CR) or CR with incomplete blood count recovery